Frontlight ResearchEarly access
Active, not recruitingPhase 2/3
An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II
Key facts
- Who runs it
- JCR Pharmaceuticals Co., Ltd.
- Where
- Japan20 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2/3
- People taking part
- 27 people enrolled
- Started
- 1 Sept 2019
- Expected to end
- 31 Mar 2030
- Type of study
- Interventional
- Treatments tested
- JR-141
- Record updated
- 3 September 2026
Who can take part
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- A patient who participated in the preceding Study JR-141-301 and completed the Week 52 visit, and has no safety concerns to enter this study in the opinion of the investigator or subinvestigator
- A patient capable of providing written informed consent in person (However, this is not required for patients aged younger than 20 years at the time of consent or patients with intellectual disability associated with MPS II whose willingness cannot be verified.)
- For patients aged younger than 20 years at the time of consent or patients with intellectual disability associated with MPS II whose willingness cannot be verified, written consent must be obtained from the legally acceptable representative. (Wherever possible, written consent of the patient should be obtained.)
- Male patient whose partner is of child-bearing potential and agrees to use a medically accepted, highly effective method of contraception
Who cannot take part
- A patient who used any concomitant medication or therapy that could affect study assessments in the opinion of the investigator or subinvestigator
- A patient with a history of serious drug allergy or hypersensitivity that precludes participation in this study in the opinion of the investigator or subinvestigator
- A patient judged to be ineligible by the investigator or subinvestigator for other reasons
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Multicenter, open-label, single-group, designed to evaluate the long term efficacy and safety of study drug for the treatment of the MPS II.
The group in the trial
- JR-141Treatment being tested
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 3 September 2026